Literature DB >> 12408781

Amebic Liver Abscess.

Wolfram Goessling1, Raymond T. Chung.   

Abstract

Amebic liver abscess should be suspected in travelers returning from endemic areas or in immunocompromised patients who present with fever, right upper quadrant pain, hepatomegaly, and a liver lesion on an imaging study. Rapid initiation of therapy without serologic confirmation of infection, if necessary, is important to minimize complications. Metronidazole is given orally or intravenously for 14 days. The drug is generally well tolerated and leads to resolution of symptoms in most patients within 2 to 3 days. It is effective against luminal cysts in only 50% of patients and, therefore, must be followed by a course of treatment with paromomycin (Humatin; Parke-Davis, Morris Plains, NJ) or another luminal antiamebic agent to eradicate the parasite. Image-guided drainage of an amebic liver abscess is indicated in patients who do not respond to antimicrobial therapy or who are at risk of abscess rupture. Surgery is reserved for patients with a ruptured abscess. Although medical therapy is generally successful in the treatment of infection caused by Entamoeba histolytica, the development of potent vaccines will be needed for worldwide eradication of disease attributable to E. histolytica.

Entities:  

Year:  2002        PMID: 12408781     DOI: 10.1007/s11938-002-0032-z

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  27 in total

Review 1.  Diagnosis and management of amebiasis.

Authors:  W A Petri; U Singh
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

2.  Common presentations of amebic liver abscess.

Authors:  R J Hoffner; T Kilaghbian; V I Esekogwu; S O Henderson
Journal:  Ann Emerg Med       Date:  1999-09       Impact factor: 5.721

3.  Perforated amebic liver abscesses: successful percutaneous treatment.

Authors:  J G Ken; E vanSonnenberg; G Casola; R Christensen; A M Polansky
Journal:  Radiology       Date:  1989-01       Impact factor: 11.105

4.  Diagnosis of amebic liver abscess and intestinal infection with the TechLab Entamoeba histolytica II antigen detection and antibody tests.

Authors:  R Haque; N U Mollah; I K Ali; K Alam; A Eubanks; D Lyerly; W A Petri
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

Review 5.  Amebic liver abscess.

Authors:  M A Hughes; W A Petri
Journal:  Infect Dis Clin North Am       Date:  2000-09       Impact factor: 5.982

Review 6.  Protozoa. Amebiasis.

Authors:  E Li; S L Stanley
Journal:  Gastroenterol Clin North Am       Date:  1996-09       Impact factor: 3.806

7.  A nested, multiplex, PCR assay for the simultaneous detection and differentiation of Entamoeba histolytica and Entamoeba dispar in faeces.

Authors:  A Evangelopoulos; G Spanakos; E Patsoula; N Vakalis; N Legakis
Journal:  Ann Trop Med Parasitol       Date:  2000-04

8.  Prognostic markers in amebic liver abscess: a prospective study.

Authors:  M P Sharma; S Dasarathy; N Verma; S Saksena; D K Shukla
Journal:  Am J Gastroenterol       Date:  1996-12       Impact factor: 10.864

9.  Intrahepatic amebic abscesses: indications for and results of percutaneous catheter drainage.

Authors:  E vanSonnenberg; P R Mueller; H R Schiffman; J T Ferrucci; G Casola; J F Simeone; O A Cabrera; B B Gosink
Journal:  Radiology       Date:  1985-09       Impact factor: 11.105

10.  Ruptured amebic liver abscess.

Authors:  G C Greaney; T B Reynolds; A J Donovan
Journal:  Arch Surg       Date:  1985-05
View more
  2 in total

1.  Caudate lobe amebic abscesses: percutaneous image-guided aspiration or drainage.

Authors:  Tanya Yadav; Ranjan K Patel; Akash Bansal; Navojit Chatterjee; Yashwant Patidar; Amar Mukund
Journal:  Abdom Radiol (NY)       Date:  2021-12-29

2.  Prognostic indications of the failure to treat amoebic liver abscesses.

Authors:  Martín Sánchez-Aguilar; Onofre Morán-Mendoza; Miguel F Herrera-Hernández; Juan Francisco Hernández-Sierra; Peter B Mandeville; J Humberto Tapia-Pérez; Martín Sánchez-Reyna; José Juan Sánchez-Rodríguez; Antonio Gordillo-Moscoso
Journal:  Pathog Glob Health       Date:  2012-08       Impact factor: 2.894

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.